Inhibrx Biosciences (INBX) Expected to Release Quarterly Earnings on Friday

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Friday, November 13th. Analysts expect Inhibrx Biosciences to post earnings of ($2.45) per share and revenue of $1.90 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). On average, analysts expect Inhibrx Biosciences to post ($9.91) EPS for the current fiscal year and ($9.34) EPS for the next fiscal year.

Inhibrx Biosciences Stock Performance

INBX stock opened at $80.28 on Friday. The firm has a 50 day moving average of $99.62 and a 200-day moving average of $91.74. Inhibrx Biosciences has a 12 month low of $57.30 and a 12 month high of $155.29.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a report on Monday, August 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Friday, September 11th. Citigroup reissued a “market perform” rating on shares of Inhibrx Biosciences in a report on Friday, September 18th. Finally, HC Wainwright assumed coverage on shares of Inhibrx Biosciences in a research report on Monday, August 24th. They set a “buy” rating and a $245.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Inhibrx Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $197.50.

Check Out Our Latest Research Report on Inhibrx Biosciences

Insiders Place Their Bets

In other Inhibrx Biosciences news, Director Douglas Forsyth purchased 2,500 shares of the stock in a transaction on Tuesday, September 8th. The shares were purchased at an average price of $114.65 per share, with a total value of $286,625.00. Following the acquisition, the director directly owned 227,064 shares in the company, valued at approximately $26,032,887.60. The trade was a 1.11% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mark Lappe purchased 25,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were acquired at an average price of $105.82 per share, with a total value of $2,645,500.00. Following the transaction, the chief executive officer owned 730,548 shares in the company, valued at approximately $77,306,589.36. The trade was a 3.54% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 62,540 shares of company stock valued at $6,347,507 and have sold 1,500 shares valued at $168,590. 18.26% of the stock is owned by corporate insiders.

Inhibrx Biosciences Company Profile

(Get Free Report)

Inhibrx Biosciences, Inc is a biotechnology company focused on developing biologic medicines for serious and rare diseases. The company uses its proprietary protein-engineering and antibody-development platforms to create therapies designed to address conditions with limited treatment options.

Its lead investigational program was INBRX-101, an engineered recombinant protein developed for alpha-1 antitrypsin deficiency-associated lung disease. The company also advanced other potential treatments, including INBRX-109, an investigational therapy studied in certain solid tumors, and additional biologic candidates targeting oncology and other serious diseases.

Read More

Earnings History for Inhibrx Biosciences (NASDAQ:INBX)

Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.